A patient with myelodysplastic syndrome showed numerous scattered red lesions on the face and trunk after 1 month of intravenous injection of camrelizumab. One popular with a diameter of about 3 mm was in a special position in the palpebral margin. Combined with medical history and clinical features,the patient was diagnosed as reactive cutaneous capillary endothelial proliferation(RCCEP) of the palpebral margin. At follow-up 6 months after the patient stopped calerizumab,the lesions subsided. Camrelizumab plays an important role in the treatment of myelodysplastic syndrome, and can cause adverse reactions such as RCCEP, which is self-limiting after withdrawal.
A patient with myelodysplastic syndrome showed numerous scattered red lesions on the face and trunk after 1 month of intravenous injection of camrelizumab. One popular with a diameter of about 3 mm was in a special position in the palpebral margin. Combined with medical history and clinical features,the patient was diagnosed as reactive cutaneous capillary endothelial proliferation(RCCEP) of the palpebral margin. At follow-up 6 months after the patient stopped calerizumab,the lesions subsided. Camrelizumab plays an important role in the treatment of myelodysplastic syndrome, and can cause adverse reactions such as RCCEP, which is self-limiting after withdrawal.
With the widespread application of functional intraocular lense (IOL), the accuracy of refractive prediction in cataract patients is increasingly important. Although IOL power calculation formulas have been innovated continuously in recent years, there are still challenges in predicting refractive powerin cataract patients with abnormal anatomical parameters, ocular comorbidities, or a history of ocular surgery. Based on the the characteristics of biological parameters and medical history to selcet appropriate IOL power formula, it is an important guarantee for accurate refractive prediction in cataract patients.
AIM： To explore the clinical treatment of peripheral necrotizing keratitis after femtosecond laser-assisted??in situ?keratomileusis (FS-LASIK). METHODS：Retrospective case-control study. A total of 18,448 cases of FS-LASIK were collected in our hospital from 2022-06/2023-05. 22 cases and 39 eyes of patients with peripheral necrotizing keratitis were observed. The scope of peripheral corneal necrosis were examined under a slit lamp microscope and treated accordingly. And 30 cases of patients who were operated on the same day were randomly selected as the control group. Observe the changes in naked eye visual acuity, diopters and intraocular pressure between the two groups after cure. RESULTS：Among the 18,448 cases, 22 patients and 39 eyes with peripheral necrotizing keratitis were found, with an incidence rate of 1.2‰, including 4 males and 18 females, aged 31 ± 5.0 years old. Topical tobramycin and dexamethasone eye drops were administered once an hour and in descending order every other day. The patient's pain, foreign body sensation, and tearing symptoms were significantly relieved. Most of the peripheral corneal necrosis lesions improved in 1 week, and gradually healed to form interlaminar clouds in 2 weeks. After treatment, the naked eye visual acuity, intraocular pressure, and diopters of the PNK group showed no significant changes compared with those of the control group. No glucocorticoid-induced intraocular hypertension occurred. CONCLUSION：Topical tobramycin and dexamethasone eye drops have a good therapeutic effect on peripheral necrotizing keratitis. The necrotic area forms scars after healing. The PNK case in this article is limited to the periphery and has no significant impact on naked eye vision, intraocular pressure, and diopters. KEYWORDS：Femtosecond laser-assisted??in situ?keratomileusis; Peripheral necrotizing keratitis; Diffuse lamellar keratitis; Postoperative complications; Glucocorticoids
Leukemia is a kind of myeloproliferative malignant clonal disease, its first symptoms are diverse, but with vision for first symptoms rare [1], with fever, fatigue, liver and spleen galomegaly for first symptoms, through this paper reported 1 case with vision for for chronic granular leukemia cases, for future clinical work experience, in order to improve the early diagnosis, avoid misdiagnosis, diagnosis.
Abstract: Objective To retrieve and analyze the clinical trials of Chinese medicine against dry eye disease(Dry eye disease，DED) included in the China Clinical Trial Registry (ChiCTR), and to understand their distribution characteristics and development trends. Methods A computerized search was performed on the clinical trials related to the prevention and treatment of dry eye in TCM included in ChiCTR from the establishment of the database to January 27, 2024, data were extracted and entered into Excel 365 for de-emphasis, and the included data were statistically analysed using the SPSS 26.0 software, and the corresponding charts were plotted to summarize the characteristics of the clinical trials. Results A total of 29 clinical trials were included, of which 24 were pre-registered. The registered research projects involved 8 provincial administrative regions and 21 clinical trial organizations in Shanghai, Beijing, Guangdong, Hunan, Zhejiang, Fujian, Shenzhen, and Hubei provinces, among which the Shanghai Institute of Acupuncture and Meridian Research (7 projects, 24.14%) registered the largest number of projects. The sources of funding were mainly 13 local finance (43.33%), self-funding (26.67%), university research funding (10.00%), pharmaceutical company funding (10.00%), hospital funding (6.67%), and national financial support (3.33%). The types of studies were mostly intervention studies (24, 87.76%), and the study design was most frequently randomized parallel controlled studies (25, 86.20%). Interventions included acupuncture, classic Chinese herbal formulas/hospital-made formulas, and proprietary Chinese medicines, and outcome indicators included primary, secondary, side effect, and additional indicators. Conclusion The rise in the number of clinically registered trials of Chinese medicine against dry eye in China tends to stabilize, the distribution of registration areas is not balanced, and the filling of clinical trial data is incomplete and not standardized, and the follow-up should strengthen the training of investigators about clinical trial registration and improve the awareness of clinical trial registration among investigators.
Abstract Aim: The objective of this study was to investigate the prognosis of massive vitreous hemorrhage (VH) secondary to polypoidal choroidal vasculopathy (PCV) after vitrectomy. Methods: Forty-nine eyes in 48 patients with PCV and breakthrough VH who underwent 23-gauge pars plana vitrectomy between January 2015 and December 2020 were enrolled. The main outcome parameters were best-corrected visual acuity, postoperative adverse events, and reoperation. Results: The average follow-up time was 20.0±15.82 months. The average preoperative best-corrected visual acuity (BCVA) was 2.12±0.65 logarithm of the minimum angle of resolution (logMAR), the BCVA at six months was 1.65±0.64 logMAR, and the six-month follow-up BCVA was 1.67±0.76 logMAR. Compared to the average preoperative BCVA, the six-months and last follow-up BCVA after vitrectomy improved (P<0.05). Postoperative complications were observed in 10 eyes (20.4%), including recurrent retinal detachment, recurrent vitreous hemorrhage, macular hole, hyphema and lens dislocation. Fourteen eyes (28.6%) underwent cataract surgery procedure an average of 10.16±5.14 months after vitrectomy. BCVA one week and three months after cataract surgery improved compared to BCVA before cataract surgery (P<0.05). Conclusions: Although the prognosis of vitrectomy varies greatly, cataract surgery could be considered to improve BCVA if polypoidal lesions are inactive six months after vitrectomy. Keywords: polypoidal choroidal vasculopathy; vitreous hemorrhage; vitrectomy; visual acuity
Objective: To understand the situation of non proliferative diabetic retinopathy (NPDR) in Kashi by optical coherence tomography angiography (OCTA). Method: 32 patients with NPDR who visited our hospital from August 2022 to April 2023 were included in the study, and 50 patients were included in the normal control group. Obtain two sets of OCTA data, including the Superficial Retinal Vascular Plexus (SVP), Deep Retinal Vascular Plexus (DVP), and Foveal Avascular Zone (FAZ) areas, and compare the differences in different indicators between the two groups. Results: 11 men (34.375%) in the NPDR group, with an average age of 58 ± 9.89 years, an average number of years with diabetes of 13.39 ± 7.2, an average glycosylated hemoglobin value of 9.48 ± 2.28 mmol/L, and the best corrected visual acuity (BCVA) (decimal visual acuity) of 0.54 ± 0.3. There were 50 cases in the normal control group and 21 cases (42%) in males. The best corrected visual acuity (BCVA) was 0.97 ± 0.12. The SVP blood flow density (%) in the NPDR group was (21.65 ± 5.38), while the normal control group was (26.36 ± 6.23). The DVP blood flow density (%) in the NPDR group was (19.12 ± 4.3), while the normal control group was (27.51 ± 2.95). The FAZ area (mm2) in the NPDR group was (0.51 ± 0.15), while the normal control group was (0.41 ± 0.14). Compared with the normal control group, the SVP blood flow density and DVP blood flow density in the NPDR group were significantly reduced, while the FAZ area was significantly increased, And it has statistical significance (P=0.001, P<0.001, P=0.003, respectively). Glycated hemoglobin (HbA1c) was negatively correlated with SVP blood flow density (%) and DVP blood flow density (%) (Pearson correlation coefficients were -0.381, P=0.032 and -0.583, P<0.001), while glycated hemoglobin (HbA1c) was not significantly correlated with FAZ area (Pearson correlation coefficient was -0.203, P=0.301). Conclusion: The blood flow density and FAZ area of non proliferative diabetes retinopathy patients in Kashgar have changed on OCTA, which is of great significance for early detection and treatment of the disease.
Objective: To understand the situation of non proliferative diabetic retinopathy (NPDR) in Kashi by optical coherence tomography angiography (OCTA). Method: 32 patients with NPDR who visited our hospital from August 2022 to April 2023 were included in the study, and 50 patients were included in the normal control group. Obtain two sets of OCTA data, including the Superficial Retinal Vascular Plexus (SVP), Deep Retinal Vascular Plexus (DVP), and Foveal Avascular Zone (FAZ) areas, and compare the differences in different indicators between the two groups. Results: 11 men (34.375%) in the NPDR group, with an average age of 58 ± 9.89 years, an average number of years with diabetes of 13.39 ± 7.2, an average glycosylated hemoglobin value of 9.48 ± 2.28 mmol/L, and the best corrected visual acuity (BCVA) (decimal visual acuity) of 0.54 ± 0.3. There were 50 cases in the normal control group and 21 cases (42%) in males. The best corrected visual acuity (BCVA) was 0.97 ± 0.12. The SVP blood flow density (%) in the NPDR group was (21.65 ± 5.38), while the normal control group was (26.36 ± 6.23). The DVP blood flow density (%) in the NPDR group was (19.12 ± 4.3), while the normal control group was (27.51 ± 2.95). The FAZ area (mm2) in the NPDR group was (0.51 ± 0.15), while the normal control group was (0.41 ± 0.14). Compared with the normal control group, the SVP blood flow density and DVP blood flow density in the NPDR group were significantly reduced, while the FAZ area was significantly increased, And it has statistical significance (P=0.001, P<0.001, P=0.003, respectively). Glycated hemoglobin (HbA1c) was negatively correlated with SVP blood flow density (%) and DVP blood flow density (%) (Pearson correlation coefficients were -0.381, P=0.032 and -0.583, P<0.001), while glycated hemoglobin (HbA1c) was not significantly correlated with FAZ area (Pearson correlation coefficient was -0.203, P=0.301). Conclusion: The blood flow density and FAZ area of non proliferative diabetes retinopathy patients in Kashgar have changed on OCTA, which is of great significance for early detection and treatment of the disease.
